2021
Neuroinflammation Associated With Tumor Necrosis Factor-α Inhibitor Exposure
Yu AW, Pecsok M, Longbrake EE, Wesley SF. Neuroinflammation Associated With Tumor Necrosis Factor-α Inhibitor Exposure. Neurology Clinical Practice 2021, 11: e488-e496. PMID: 34484946, PMCID: PMC8382406, DOI: 10.1212/cpj.0000000000001014.Peer-Reviewed Original ResearchMRI findingsBrain MRIYale New Haven Health SystemNonspecific MRI findingsRetrospective cohort studyCommon abnormal findingDetailed chart reviewRisk stratification parametersElectronic medical recordsAdditional immunotherapyNeuroinflammatory phenomenaTNFi discontinuationTNFi exposureChart reviewCohort studyAbnormal findingsPeriod prevalenceT2 hyperintensityAutoimmune diseasesClinical spectrumInhibitor exposureMedical recordsTumor necrosisTNFiNeuroinflammation
2016
Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice
Longbrake EE, Cross AH, Salter A. Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice. Multiple Sclerosis Journal - Experimental Translational And Clinical 2016, 2: 2055217316677868. PMID: 28280599, PMCID: PMC5340186, DOI: 10.1177/2055217316677868.Peer-Reviewed Original ResearchDisease-modifying therapiesMultiple sclerosis activityInjectable disease-modifying therapiesOral disease-modifying therapiesMultiple sclerosisInjectable therapiesBaseline differencesClinical practiceRetrospective cohort studyProportional hazards modelDrug discontinuationCohort studyDiscontinuation ratesTreatment groupsHazards modelSclerosisPatientsTherapyRelative efficacyTolerabilityFurther studiesHigher proportionEfficacyExpert opinionTreatment
2015
Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance
Longbrake EE, Naismith RT, Parks BJ, Wu GF, Cross AH. Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance. Multiple Sclerosis Journal - Experimental Translational And Clinical 2015, 1: 2055217315596994. PMID: 26550483, PMCID: PMC4636217, DOI: 10.1177/2055217315596994.Peer-Reviewed Original ResearchDimethyl fumarateMultiple sclerosisRisk factorsClinical significanceGrade 2Lower baseline absolute lymphocyte countBaseline absolute lymphocyte countSingle academic medical centerDMF-induced lymphopeniaDMF-treated patientsRetrospective cohort studyAbsolute lymphocyte countGood clinical responseProgressive multifocal leukoencephalopathyDisease-modifying therapiesFraction of patientsReal-world populationAcademic medical centerLymphocyte monitoringNatalizumab exposureMultifocal leukoencephalopathyClinical responseCohort studyLymphocyte countOlder patients